Development of a novel platform technology for the generation and maturation of fully human antibodies (S2403CNR).

Activity: Consultancy types › KTP & Consultancy in kind

Description

Knowledge Transfer Partnership between QUB and Fusion Antibodies Ltd. £232,264. Co-Inv (50%)
Period01 Feb 2017 → 31 Jan 2020
Work forFusion Antibodies plc, United Kingdom
Degree of RecognitionNational